Pharmaceutical composition for treating palmoplantar pustulosis
The MEK inhibitor-based pharmaceutical composition addresses the lack of effective treatments for palmoplantar pustulosis by targeting the RAS/RAF/MEK/ERK pathway, achieving rapid pustule elimination and symptom relief.
Patent Information
- Application Number
- JP2023082408
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is no effective treatment method for palmoplantar pustulosis, a condition characterized by recurrent blisters and pustules on the palms and soles, causing psychological distress and skin impairment, with unknown pathogenic mechanisms.
A pharmaceutical composition comprising MEK inhibitors, such as trametinib, is administered to treat palmoplantar pustulosis, targeting the RAS/RAF/MEK/ERK signaling pathway to eliminate blisters and improve associated symptoms.
The MEK inhibitor effectively eliminates pustules and improves symptoms like joint pain within two weeks of administration, demonstrating a novel therapeutic approach for palmoplantar pustulosis.
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition for treating palmoplantar pustulosis. [Background technology]
[0002] Palmoplantar pustulosis (PPP) is a disease in which lesions such as blisters and pustules are repeatedly formed mainly on the palms and soles of the feet. In addition to the palms and soles of the feet, symptoms may appear on the shins, knees, elbows, head, etc., and may be accompanied by nail deformation and pain in the bones and joints. The number of patients in Japan is estimated to be about 140,000 (Non-Patent Document 1), and the peak incidence rate is after middle age. Since the pustules are sterile, it is not a disease that can be transmitted to others, but since they occur in areas that are easily noticeable to others, such as the palms and soles of the feet, they are accompanied by mental distress. Furthermore, as the skin symptoms worsen, the skin becomes more susceptible to cracking, which impairs the quality of life of the patient. At present, the mechanism of onset is unknown.
[0003] There is no standard treatment for palmoplantar pustulosis, and the treatment usually involves applying topical steroids or topical active vitamin D3, PUVA therapy, administration of retinoids, methotrexate, cyclosporine, etc. Recently, it has been reported that administration of IL-36R antibodies can eliminate skin symptoms (Patent Document 1). However, currently, no effective treatment for palmoplantar pustulosis has been established. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] WO2020 / 136101 [Non-patent literature]
[0005] [Non-Patent Document 1] Kubota et al., BMJ Open 5: e006450 2015. Summary of the Invention [Problem to be solved by the invention]
[0006] In view of the above circumstances, an objective of the present invention is to provide a pharmaceutical composition for treating palmoplantar pustulosis, and a method for treating palmoplantar pustulosis using the pharmaceutical composition. [Means for solving the problem]
[0007] The inventors administered the MEK inhibitor trametinib to patients with palmoplantar pustulosis for two weeks and found that the pustules on the palms and feet completely disappeared two days after the start of administration. Based on the above findings, the present invention has been completed.
[0008] That is, the present invention relates to the following (1) and (2). (1) A pharmaceutical composition for treating palmoplantar pustulosis, the composition comprising a MEK inhibitor. (2) The composition according to (1) above, wherein the MEK inhibitor is one or more selected from the group consisting of trametinib, binimetinib, selumetinib, cobimetinib, pimasertib, refametinib, ulixertinib, abemaciclib, U0126, PD184352 (CI-1040), PD98059 and BIX 02189. In this specification, the symbol "~" indicates a numerical range including the values on either side of it. Effect of the Invention
[0009] INDUSTRIAL APPLICABILITY The present invention provides a pharmaceutical composition for treating palmoplantar pustulosis, and a method for treating palmoplantar pustulosis using the pharmaceutical composition. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] The present inventors confirmed that when a MEK inhibitor was administered to a patient with palmoplantar pustulosis for two weeks, the pustules on the palms and feet completely disappeared. That is, the present inventors demonstrated for the first time that a MEK inhibitor has an effect as a therapeutic agent for palmoplantar pustulosis.
[0011] MEK (MAPK / ERK kinase) is a dual-specificity serine / threonine kinase that phosphorylates serine and threonine residues of ERK (extracellular signal-regulated kinase) 1 and ERK 2 in the RAS / RAF / MEK / ERK signaling pathway, activating ERK1 / 2. In normal cells, Ras activated by extracellular growth factor stimulation binds to Raf to promote its activation, Raf phosphorylates and activates MEK, and MEK then phosphorylates and activates ERK. Activated ERK translocates from the cytoplasm to the nucleus, where it activates transcription factors such as ELK, CREB, c-Myc, c-Fos, and Sp-1 to induce gene expression. The pathway in which information for gene expression is transmitted by the phosphorylation cascade from RAS to ERK is called the RAS / RAF / MEK / ERK signaling pathway. There are two subtypes of MEK: MEK1 and MEK2. As used herein, "MEK" includes both MEK1 and MEK2.
[0012] Hereinafter, an embodiment of the present invention will be described. Note that, when the term "the present embodiment" is used, it refers to all embodiments described in this specification unless otherwise specified. The first embodiment is a pharmaceutical composition for treating palmoplantar pustulosis, the composition comprising a MEK inhibitor (hereinafter also referred to as "the pharmaceutical composition according to this embodiment"). Alternatively, the first embodiment is the use of a MEK inhibitor for producing a pharmaceutical composition for treating palmoplantar pustulosis. "Treatment" of palmoplantar pustulosis means disappearance of blisters or pustules on the palms and soles in palmoplantar pustulosis, and / or improvement of symptoms other than skin symptoms in palmoplantar pustulosis, such as bone joint symptoms.
[0013] The MEK inhibitor of the present embodiment is not particularly limited, but examples thereof include trametinib (CAS: 871700-17-3), binimetinib (CAS: 606143-89-9), selumetinib (CAS: 606143-52-6), cobimetinib (CAS: 934660-93-2), pimasertib (CAS: 1236699-92-5), and refametinib. (CAS:923032-37-5), ulixertinib (CAS:869886-67-9), abemaciclib (CAS:1231929-97-7), U0126 (CAS:1173097-76-1), PD184352 (CI-1040) (CAS:212631-79-3), PD98059 (CAS:167869-21-8) and BIX 02189 (CAS:1094614-85-3). In addition to these compounds, other examples include antibodies and peptide aptamers that suppress or inhibit MEK activity, as well as substances that suppress or inhibit the expression of the MEK gene, such as siRNA and miRNA.
[0014] The dosage form of the pharmaceutical composition according to the present embodiment includes tablets, capsules, granules, powders, syrups, suspensions, suppositories, ointments, creams, gels, patches, inhalants, injections, etc. These preparations are prepared according to conventional methods. In the case of liquid preparations, they may be dissolved or suspended in water or other suitable solvents when used. In addition, tablets and granules may be coated by known methods. In the case of injections, the active ingredient is prepared by dissolving it in water, but it may also be dissolved in physiological saline or glucose solution as necessary, and a buffer or preservative may also be added.
[0015] Preparations for oral or parenteral administration are provided in any formulation form. For example, the formulation may be prepared as a therapeutic agent or composition for oral administration in the form of granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions or liquids, or as a therapeutic agent or composition for parenteral administration in the form of injections, drips, transdermal absorbents, transmucosal absorbents, nasal drops, inhalants, suppositories, etc. for intravenous, intramuscular or subcutaneous administration. Injections and drips may be prepared in a powder form such as a lyophilized form, and dissolved in an aqueous medium such as physiological saline when used.
[0016] The type of formulation additives used in the production of the pharmaceutical composition according to the present embodiment, the ratio of the formulation additives to the active ingredient, or the production method of the therapeutic composition and the preventive composition can be appropriately selected by those skilled in the art depending on the form of the composition. The formulation additives can be inorganic or organic substances, or solid or liquid substances, and can generally be blended in an amount of 1% by weight to 90% by weight of the active ingredient. Specific examples of formulation additives include lactose, glucose, mannitol, dextrin, cyclodextrin, starch, sucrose, magnesium aluminometasilicate, synthetic aluminum silicate, sodium carboxymethylcellulose, hydroxypropyl starch, calcium carboxymethylcellulose, ion exchange resins, methylcellulose, gelatin, gum arabic, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, light anhydrous silicic acid, magnesium stearate, talc, tragacanth, bentonite, veegum, titanium oxide, sorbitan fatty acid esters, sodium lauryl sulfate, glycerin, fatty acid glycerin esters, purified lanolin, glycerogelatin, polysorbate, macrogol, vegetable oils, wax, liquid paraffin, white petrolatum, fluorocarbons, nonionic surfactants, propylene glycol, and water.
[0017] To prepare a solid preparation for oral administration, the active ingredient is mixed with excipients such as lactose, starch, crystalline cellulose, calcium lactate, anhydrous silicic acid, etc. to prepare a powder, or further, if necessary, a binder such as sucrose, hydroxypropylcellulose, polyvinylpyrrolidone, or a disintegrant such as carboxymethylcellulose, calcium carboxymethylcellulose, etc. is added and wet or dry granulated to prepare a granule. To prepare tablets, these powders and granules may be tableted as is, or with the addition of a lubricant such as magnesium stearate or talc. These granules or tablets may be coated with an enteric base such as hydroxypropylmethylcellulose phthalate or methacrylic acid-methyl methacrylate polymer to prepare an enteric coated preparation, or coated with ethylcellulose, carnauba wax, hardened oil, etc. to prepare a sustained release preparation. To prepare capsules, the powders or granules may be filled into a hard capsule, or the active ingredient may be dissolved in glycerin, polyethylene glycol, sesame oil, olive oil, etc., and then coated with a gelatin membrane to prepare a soft capsule.
[0018] To produce an injection, the active ingredient is dissolved in distilled water for injection, if necessary, together with a pH adjuster such as hydrochloric acid, sodium hydroxide, lactose, lactic acid, sodium, sodium monohydrogen phosphate, sodium dihydrogen phosphate, etc., and an isotonicity agent such as sodium chloride, glucose, etc., and then sterile filtered and filled into an ampoule, or it may be further added with mannitol, dextrin, cyclodextrin, gelatin, etc., and then vacuum lyophilized to produce an injection that is dissolved when used. Also, the active ingredient may be added with lecithin, polysorbate 80, polyoxyethylene hydrogenated castor oil, etc., and emulsified in water to produce an emulsion for injection.
[0019] To prepare a rectal preparation, the active ingredient may be dissolved by wetting together with a suppository base such as cacao butter, tri-, di-, or monoglyceride of fatty acid, or polyethylene glycol, and then poured into a mold and cooled; alternatively, the active ingredient may be dissolved in polyethylene glycol, soybean oil, or the like, and then coated with a gelatin film.
[0020] The dosage and frequency of administration of the pharmaceutical composition according to this embodiment are not particularly limited, and can be appropriately selected at the discretion of a physician depending on conditions such as the purpose of treatment and the weight and age of the patient. In general, the daily oral dose for adults is about 0.01 to 1000 mg (weight of active ingredient), and can be administered once a day or in divided doses, or every few days. When used as an injection, it is desirable to administer 0.001 to 100 mg (weight of active ingredient) to adults continuously or intermittently.
[0021] The pharmaceutical composition according to the present embodiment may be prepared as a sustained release formulation, such as an implant and a microencapsulated delivery system, using a pharma- ceutically acceptable carrier that can prevent immediate removal from the body. Such carriers include biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such materials can be easily prepared by those skilled in the art. Suspensions of liposomes can also be used as pharma-ceutically acceptable carriers. Liposomes can be prepared as lipid compositions, including but not limited to phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanol (PEG-PE), by passing through a filter of appropriate pore size to a size suitable for use, and purified by reverse phase evaporation.
[0022] The pharmaceutical composition according to this embodiment may be provided in the form of a kit together with instructions on the administration method, etc. The drug contained in the kit is supplied in a container made of a material that effectively maintains the activity of the drug for a long period of time, does not adsorb to the inside of the container, and does not alter the components. For example, a sealed glass ampoule may contain a buffer or the like sealed in the presence of a neutral, non-reactive gas such as nitrogen gas. The kit may also include an instruction manual. The instruction manual may be provided to the user in the form of a printed sheet of paper or in the form of an electromagnetically readable medium such as a CD-ROM or DVD-ROM.
[0023] The second embodiment is a method for treating palmoplantar pustulosis, comprising administering a composition containing a MEK inhibitor (the pharmaceutical composition for treatment according to this embodiment) to a subject to be treated. Here, "treatment" refers to disappearance of blisters or pustules on the palms and soles of the feet in palmoplantar pustulosis, and / or improvement of symptoms other than skin symptoms in palmoplantar pustulosis, such as bone and joint symptoms.
[0024] The subjects of the treatment method for palmoplantar pustulosis according to the present embodiment are not particularly limited, but are preferably mammals such as humans, pet animals such as dogs, cats, rabbits, and ferrets, and livestock animals such as cows, pigs, sheep, and horses, and a particularly preferred "mammal" is humans.
[0025] When this specification is translated into English and includes the singular words "a," "an," and "the," it is intended to include the plural as well as the singular, unless the context clearly indicates otherwise. In addition, in this specification, "to the same extent" and "about" refer to a numerical range of ±10%. The present invention will be further described below with reference to examples. However, these examples are merely illustrative of embodiments of the present invention and are not intended to limit the scope of the present invention. EXAMPLES
[0026] MEK inhibitors were administered to subjects with palmoplantar pustulosis who were participants in a clinical trial of a disease unrelated to palmoplantar pustulosis. In this study, trametinib was used as the MEK inhibitor. Trametinib manufactured by Novartis Pharma was used. A subject with palmoplantar pustulosis was orally administered trametinib at half the usual dose (1.0 mg / day) of the antitumor drug every day for two weeks. As a result, it was confirmed that the pustules on the palms and soles of the subject had completely disappeared on the second day of administration. Furthermore, it was confirmed that the knee joint pain, which is thought to be associated with palmoplantar pustulosis, in the subject had improved. In addition, palmoplantar pustulosis recurred on the palms and soles of the feet about 10 days after the subject had completed the two-week treatment with trametinib. Therefore, it is believed that continuous use of MEK inhibitors is necessary for the treatment of palmoplantar pustulosis. [Industrial Applicability]
[0027] The therapeutic pharmaceutical composition of the present invention is believed to be effective in improving the symptoms of palmoplantar pustulosis, and is therefore expected to be useful in the medical field.
Claims
1. A pharmaceutical composition for treating palmoplantar pustulosis, the composition comprising a MEK inhibitor.
2. 2. The composition of claim 1, wherein the MEK inhibitor is one or more selected from the group consisting of trametinib, binimetinib, selumetinib, cobimetinib, pimasertib, refametinib, ulixertinib, abemaciclib, U0126, PD184352 (CI-1040), PD98059, and BIX 02189.
Citation Information
Patent Citations
Anti-il-36r antibodies for treatment of palmoplantar pustulosis
WO2020136101A1
